Intech Biopharm Corporation (TPEX:6461)

Intech Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	50.39	16.8	198.65	77.73	64.82	220.48
Short-Term Investments	142.5	197.5	60	520	310	115
Cash & Short-Term Investments	192.89	214.3	258.65	597.73	374.82	335.48
Cash Growth	-6.90%	-17.15%	-56.73%	59.47%	11.73%	10.11%
Accounts Receivable	12.4	4.38	9.28	3.05	3.67	15.04
Other Receivables	65.31	2.59	9.83	8.7	7.94	7.94
Receivables	77.7	6.97	19.11	11.74	11.6	22.98
Inventory	104.26	116.48	63.86	41.53	51.82	59.87
Prepaid Expenses	20.45	65.38	68.65	43.62	40.7	33.74
Other Current Assets	0.3	-	0.06	0.41	0.13	4.26
Total Current Assets	395.6	403.13	410.32	695.02	479.06	456.33
Property, Plant & Equipment	1,390	1,403	1,885	1,900	2,009	2,090
Other Intangible Assets	4.56	4.89	3.86	4.88	4.8	4.62
Long-Term Deferred Tax Assets	24.77	24.77	24.77	24.77	24.77	24.77
Other Long-Term Assets	512.46	514.69	71.69	86.15	33.17	26.26
Total Assets	2,328	2,351	2,396	2,711	2,551	2,602

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	11.67	3.9	9.82	0.31	1.33	2.4
Accrued Expenses	25.8	26.44	28.82	19.24	23.71	20.82
Short-Term Debt	80	-	-	-	-	-
Current Portion of Long-Term Debt	275.09	192.73	248.82	464.65	265.26	211.66
Current Portion of Leases	0.39	0.39	-	-	-	-
Current Unearned Revenue	12.94	12.94	81.18	78.54	78.31	78.99
Other Current Liabilities	5.31	6.92	18	5.99	5.23	9.35
Total Current Liabilities	411.2	243.32	386.64	568.73	373.82	323.22
Long-Term Debt	912.54	994.9	1,188	970.41	1,143	940.77
Long-Term Leases	0.51	0.6	-	-	-	-
Long-Term Unearned Revenue	8.84	8.84	5.53	2.35	-	-
Pension & Post-Retirement Benefits	1.33	0.85	-	-	-	-
Long-Term Deferred Tax Liabilities	0.02	0.02	-	-	-	-
Other Long-Term Liabilities	1.45	1.45	1.72	1.74	1.54	-
Total Liabilities	1,336	1,250	1,582	1,543	1,519	1,264

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,784	1,784	1,379	1,374	1,170	1,163
Additional Paid-In Capital	282.41	282.09	19.76	286.16	195.15	481.32
Retained Earnings	-1,071	-959.57	-579.76	-488.08	-327.88	-301.76
Comprehensive Income & Other	-2.86	-5.58	-5.16	-4.32	-5.13	-4.72
Shareholders' Equity	991.64	1,101	814.28	1,168	1,032	1,338
Total Liabilities & Equity	2,328	2,351	2,396	2,711	2,551	2,602

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,269	1,189	1,436	1,435	1,409	1,152
Net Cash (Debt)	-1,076	-974.31	-1,178	-837.33	-1,034	-816.94
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-6.65	-6.42	-8.58	-6.95	-8.90	-8.03
Filing Date Shares Outstanding	178.35	178.41	137.94	137.41	116.96	116.28
Total Common Shares Outstanding	178.35	178.41	137.94	137.41	116.96	116.28
Working Capital	-15.6	159.81	23.68	126.3	105.24	133.11
Book Value Per Share	5.56	6.17	5.90	8.50	8.82	11.50
Tangible Book Value	987.08	1,096	810.42	1,163	1,027	1,333
Tangible Book Value Per Share	5.53	6.14	5.87	8.46	8.78	11.46
Land	516.45	516.45	919.87	919.87	950.72	950.72
Buildings	761.44	756.97	791.07	790.24	798.32	810.2
Machinery	759.16	754.83	724.87	657.12	645.9	633.52

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 26, 2026

Data Sources Report a data error